International Application No.: PCT/EP00/00425

Attorney Docket No.: BM45353

200

- 24. The isolated polypeptide of claim 19, wherein the polypeptide is according to (b).
- 25. An isolated polynucleotide encoding a polypeptide of Claim 24 or the full complement to the isolated polynucleotide.

B1/

- 26. The isolated polypeptide of claim 19, wherein the immunogenic fragment of (b) comprises at least 20 amino acids.
- 27. The isolated polypeptide of claim 19, wherein the isolated polypeptide consists of SEQ ID NO:2.
- 28. An isolated polynucleotide encoding the polypeptide of Claim 28 or the full complement to the isolated polynucleotide.
- 29. A process for expressing the polynucleotide of Claim 28 comprising transforming a host cell with an expression vector comprising the polynucleotide and culturing the host cell under conditions sufficient for expression of the polynucleotide.
- 30. A fusion protein comprising the isolated polypeptide of Claim 19.
- 31. An isolated polynucleotide comprising the polynucleotide of SEQ ID NO:1.
- 32. An isolated polynucleotide segment comprising a polynucleotide sequence or the full complement of the entire length of the polynucleotide sequence, wherein the polynucleotide sequence hybridizes to the full complement of SEQ ID NO:1 minus the complement of any stop codon, wherein the hybridization conditions include incubation at 42°C in a solution comprising: 50% formamide, 5x SSC (150mM NaCl, 15mM trisodium citrate), 50 mM sodium phosphate (pH 7.6), 5x Denhardt's solution, 10% dextran sulfate, and 20 micrograms/ml denatured, sheared salmon sperm DNA, followed by washing in 0.1x SSC at 65°C; and, wherein the polynucleotide sequence is identical to SEQ ID NO:1 minus any terminal stop codon, except that, over the entire length corresponding to SEQ ID NO:1 minus any terminal

Mi gly -B' International Application No.: PCT/EP00/00425 Attorney Docket No.: BM45353

stop codon n_n nucleotides are substituted, inserted or deleted, wherein n_n satisfies the following expression

$$n_n \le x_n - (x_n \bullet y)$$

wherein \mathbf{x}_n is the total number of nucleotides in SEQ ID NO:1 minus any terminal stop codon, \mathbf{y} is at least 0.95 and wherein any non-integer product of \mathbf{x}_n and \mathbf{y} is rounded down to the nearest integer before subtracting the product from \mathbf{x}_n ; and wherein the polynucleotide sequence detects Neisseria meningitidis.

- 33. An expression vector comprising the isolated polynucleotide of Claim 20.
- 34. A host cell transformed with the expression vector of Claim 33.
- 35. A vaccine comprising the polypeptide of Claim 19 and a pharmaceutically acceptable carrier.
- 36. The vaccine of Claim 35, wherein the vaccine comprises at least one other *Neisseria* meningitidis antigen.
- 37. An antibody immunospecific for the polypeptide or immunogenic fragment of Claim 19.
- 38. A method for inducing an immune response in a mammal comprising administration of the polypeptide of Claim 19.
- 39. A method of diagnosing a *Neisseria meningitidis* infection, comprising identifying a polypeptide of Claim 19, or an antibody that is immunospecific for the polypeptide, present within a biological sample from an animal suspected of having such an infection.
- 40. A method for inducing an immune response in a mammal comprising administration of the isolated polynucleotide of Claim 20.

SB1

91b —